Skip to main content
Back to Goldman Sachs

Goldman Sachs's Biotechnology Portfolio

Browse 16 Biotechnology companies funded by Goldman Sachs. See funding amounts, founder contacts, and investment details.

Biotechnology Companies
16
Total Funding in Biotechnology
$1.2B

Biotechnology Portfolio Companies (16)

Export
BiotechnologyHealth CareMedical

Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.

London, United Kingdom
September 2024
$100.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyEmergency MedicineGeneticsHealth CareMedical

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Boston, United States
June 2024
$100.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareMedicalTherapeutics

Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.

Watertown, United States
June 2026
$115.0M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyMedicalTherapeutics

MOMA Therapeutics operates as a biotechnology company.

Cambridge, United States
May 2022
$150.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsProduct Research

Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

Lake Forest, United States
March 2022
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyHealth DiagnosticsPharmaceuticalTherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.

Westlake Village, United States
February 2024
$150.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CarePharmaceuticalTherapeutics

Silver Creek Pharmaceuticals is a biotechnology company, develops protein therapeutics to treat cardiovascular diseases.

San Francisco, United States
February 2022
$9.2M
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

BiotechnologyNeuroscience

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Boston, United States
February 2025
$93.5M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyLife ScienceMedical

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

Cambridge, United States
May 2024
$95.0M
Series C

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyPharmaceutical

Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.

San Diego, United States
April 2024
$132.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareLife ScienceTherapeutics

Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.

Alachua, United States
January 2026
$75.0M
Series C

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyClinical TrialsOncology

TORL BioTherapeutics is a clinical-stage biopharmaceutical business.

Culver City, United States
October 2025
$96.0M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CarePharmaceutical

Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations.

Cambridge, United States
October 2022
$90.0M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth Care

Ignis Therapeutics is a innovative therapies in the field of central nervous system.

Shanghai, China
January 2023
$2.8M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyManufacturingTherapeutics

Specialty Pharmaceutical Company

Seongnam, South Korea
November 2022
Grant

Founder Contacts

30,000+ verified contacts

BiotechnologyManufacturingPharmaceutical

Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation.

Shanghai, China
August 2022
$14.7M
Series C

Founder Contacts

30,000+ verified contacts

Explore Goldman Sachs's Full Portfolio

View all companies funded by Goldman Sachs across every industry and funding stage.

View Full Goldman Sachs Portfolio